Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations].

Zhongguo fei ai za zhi = Chinese journal of lung cancer - 20 May 2022

Yang Xue, Zhao Jun

Abstract excerpt

Epidermal growth factor receptor (EGFR) exon 20 insertion mutations are the third most prevalent activating EGFR mutation in non-small cell lung cancer (NSCLC), accounting for 5%-12% of all EGFR mutations in NSCLC cases. Patients harboring EGFR exon 20 insertion mutations exhibit similar clinical characteristics except for worse prognosis as compared to those with 'classic' EGFR mutations. EGFR exon 20 insertion...

Topics

Join the communities discussing this publication.

Antibodies, Bispecific
Carcinoma, Non-Small-Cell Lung
ErbB Receptors
Exons
Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Mutagenesis, Insertional

Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 35599009
DOI: 10.3779/j.issn.1009-3419.2022.103.01
PMCID: PMC9127758

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations].PMID 35599009Read ↗

[The research status and development trend of EGFR gene exon 20 insertion mutant non-small cell lung cancer].Semantic proximity Read ↗

[EGFR Exon 20 Insertion Mutation: Research Status and New Treatment Strategies].Semantic proximity Read ↗

Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutationsSemantic proximity Read ↗

Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations.Semantic proximity Read ↗

Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non-small cell lung cancer.Semantic proximity Read ↗

[Studies and Progress of EGFR exon 20 Insertion Mutation in Non-small Cell Lung Cancer].Semantic proximity Read ↗

[Advances in the Treatment of EGFR Exon 20ins Mutant NSCLC].Semantic proximity Read ↗

The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidationSemantic proximity Read ↗

Mobocertinib: A Potential Treatment for NSCLC with EGFR Exon 20 Insertions.Semantic proximity Read ↗

Advances in the Diagnosis and Treatment of Advanced Non-Small-Cell Lung Cancer With EGFR Exon 20 Insertion Mutation.Semantic proximity Read ↗

Targeting EGFR Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer: Changes in Treatment Strategies are Coming.Semantic proximity Read ↗

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in KoreaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.